CRMD - CorMedix Inc Stock Price, Fair Value and News

5.17USD-0.24 (-4.44%)Market Closed

Market Summary

USD5.17-0.24

Market Closed

-4.44%

CRMD Stock Price

View Fullscreen

CRMD RSI Chart

CRMD Valuation

Market Cap

297.3M

Price/Earnings (Trailing)

-5.92

Price/Sales (Trailing)

4.5K

EV/EBITDA

-6.33

Price/Free Cashflow

-6.51

CRMD Price/Sales (Trailing)

CRMD Profitability

Operating Margin

100.00%

EBT Margin

-63433.82%

Return on Equity

-86.6%

Return on Assets

-73.85%

Free Cashflow Yield

-15.37%

CRMD Fundamentals

CRMD Revenue

CRMD Earnings

Earnings (TTM)

-50.2M

Earnings Growth (Yr)

-36.9%

Earnings Growth (Qtr)

1.95%

Breaking Down CRMD Revenue

Last 7 days

0.7%

Last 30 days

13.9%

Last 90 days

70.1%

Trailing 12 Months

2.1%

How does CRMD drawdown profile look like?

CRMD Financial Health

Current Ratio

6.65

CRMD Investor Care

Shares Dilution (1Y)

23.50%

Diluted EPS (TTM)

-0.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	27.2K	39.9K	52.7K	65.4K
2021	253.4K	245.2K	190.3K	14.4K
2020	193.6K	174.8K	208.3K	239.2K
2019	570.3K	598.0K	285.0K	283.3K
2018	313.0K	184.4K	495.8K	429.8K
2017	222.2K	341.9K	358.5K	329.3K
2016	220.3K	116.8K	125.3K	224.1K
2015	208.3K	288.6K	272.1K	210.1K
2014	0	0	0	189.3K
2013	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of CorMedix Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 13, 2024	todisco joseph	bought	50,718	3.74	13,561	chief executive officer
Jan 12, 2024	masson-hurlburt elizabeth	acquired	-	-	50,000	evp, head of clinical ops.
Jan 12, 2024	mistry erin	sold (taxes)	-15,229	3.47	-4,389	chief commercial officer
Jan 12, 2024	todisco joseph	acquired	-	-	133,333	chief executive officer
Jan 12, 2024	mistry erin	acquired	-	-	50,000	chief commercial officer
Jan 12, 2024	todisco joseph	sold (taxes)	-47,820	3.47	-13,781	chief executive officer
Jan 12, 2024	david matthew t	sold (taxes)	-18,099	3.47	-5,216	chief financial officer
Jan 12, 2024	masson-hurlburt elizabeth	sold (taxes)	-15,972	3.47	-4,603	evp, head of clinical ops.
Jan 12, 2024	david matthew t	acquired	-	-	50,000	chief financial officer
Dec 15, 2023	dunton alan w	bought	9,900	3.3	3,000	-

Which funds bought or sold CRMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	WELLS FARGO & COMPANY/MN	added	14.11	16,989	76,239	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	unchanged	-	10,368	91,588	-%
May 10, 2024	PNC Financial Services Group, Inc.	added	2,166	1,662	1,730	-%
May 10, 2024	LPL Financial LLC	added	140	140,208	222,176	-%
May 10, 2024	OSAIC HOLDINGS, INC.	added	53.49	7,443	17,628	-%
May 10, 2024	BlackRock Inc.	reduced	-0.59	1,595,920	14,784,900	-%
May 10, 2024	CIBC Private Wealth Group, LLC	unchanged	-	17,220	175,140	-%
May 10, 2024	CITIGROUP INC	added	19.68	10,153	39,199	-%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-41.04	-47,531	94,315	-%
May 10, 2024	VANGUARD GROUP INC	added	3.64	1,792,250	12,415,500	-%

Are Funds Buying or Selling CRMD?

Are funds buying CRMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CRMD

No. of Funds

Unveiling CorMedix Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nomura holdings inc	5.4%	2,946,531	SC 13G/A
Feb 13, 2024	vanguard group inc	5.15%	2,825,335	SC 13G
Jan 29, 2024	blackrock inc.	6.4%	3,507,695	SC 13G
Feb 14, 2023	nomura holdings inc	7.2%	2,952,334	SC 13G/A
Jul 08, 2022	blackrock inc.	1.6%	637,778	SC 13G
Feb 14, 2022	nomura holdings inc	5.3%	2,003,612	SC 13G
Feb 03, 2022	blackrock inc.	6.6%	2,500,721	SC 13G/A
Feb 11, 2021	elliott investment management l.p.	4.99%	7,136,979	SC 13D/A
Jan 29, 2021	blackrock inc.	6.2%	1,995,193	SC 13G/A
Aug 10, 2020	elliott investment management l.p.	5.8%	1,758,374	SC 13D

Recent SEC filings of CorMedix Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	S-3	S-3
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading

Peers (Alternatives to CorMedix Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.0B	6.8B	9.93%	-6.23%	-7.88	6.87	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	-2.86%	-28.22%	-57.66	9.56	75.20%	68.82%
BMRN	15.5B	2.5B	-8.14%	-14.08%	75.52	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-3.24%	-16.29%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	1.09%	107.81%	-9.83	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-22.77%	-53.41%	-12.37	9.85	394.93%	39.61%
AXSM	3.5B	251.0M	1.40%	-8.18%	-11.81	13.94	73.58%	-86.73%
ARWR	3.1B	240.7M	-5.68%	-38.85%	-6.52	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-16.31%	-29.84%	-1.5K	3.09	56.43%	98.83%
SMALL-CAP
CPRX	1.8B	411.3M	-0.76%	-10.51%	28.39	4.49	60.38%	-34.49%
NVAX	627.6M	996.6M	1.36%	-50.17%	-1.57	0.63	-26.66%	65.49%
CRBP	467.4M	881.7K	16.76%	369.92%	-13.85	481.06	-77.61%	33.36%
INO	261.3M	4.9M	-4.04%	14.81%	-1.93	53.69	-54.97%	51.71%
IBIO	6.6M	2.1M	-14.75%	74.53%	-0.24	2.14	-13.45%	66.37%

CorMedix Inc News

Latest updates

CorMedix Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-	-	-	-	29,702	6,817	21,253	7,636	22,862	38,088	8,191	88,261	55,714	93,020	16,443	74,054	24,778	59,530	35,266	163,692	26,523	372,514
Cost Of Revenue	-	818,539	-	-	406	1,469	332	1,527	48,007	25,166	14,426	61,339	57,232	79,913	19,184	48,517	46,125	79,026	21,128	226,955	22,114	312,434
Gross Profit	-Infinity%	-818,539	-	-	29,296	5,348	20,921	6,109	8,390	12,922	-6,235	26,922	-1,518	13,107	-2,741	25,537	-21,347	-19,496	14,138	-63,263	4,409	60,080
Operating Expenses	1.4%	15,885,697	15,668,744	11,017,179	8,418,524	6,967,282	8,261,366	7,038,470	7,788,310	8,577,841	5,875,993	7,237,440	6,083,122	6,616,862	8,917,868	5,637,285	5,354,477	5,152,019	5,551,494	4,859,918	-2,133,822	10,301,533
S&GA Expenses	12.5%	15,048,252	13,379,855	7,609,677	5,575,302	4,628,014	5,051,895	4,750,883	4,553,091	3,836,613	3,355,790	4,601,108	3,788,693	3,691,507	3,232,576	3,165,168	2,677,470	2,631,027	2,571,587	1,984,922	2,213,440	2,012,439
R&D Expenses	-63.4%	837,445	2,288,889	3,407,502	2,843,223	2,339,268	3,209,471	2,287,587	3,235,219	4,741,228	2,520,203	2,636,332	2,294,429	2,925,355	5,685,292	2,472,117	2,677,008	2,520,992	2,979,907	2,874,996	-4,347,261	8,289,094
EBITDA Margin	-22.7%	-632	-515	-515	-472	-594	-760	-1,040	-1,961	-141	-111	-105	-111	-	-	-	-	-	-	-	-	-
Interest Expenses	50.0%	9,835	6,556	8,776	8,776	8,776	3,585	5,378	5,378	5,381	-	5,184	5,322	7,800	13,828	6,276	6,276	172,429	306,736	302,048	-	-
Income Taxes	-Infinity%	-1,394,770	-	-	-	-	-585,617	-	-	-	-1,250,186	-	-	-3,138	-5,169,395	6,276	-	-	-5,060,778	-	-	-
Earnings Before Taxes	-Infinity%	-15,860,893	-	-10,567,226	-8,208,951	-6,853,721	-8,190,456	-	-7,790,987	-8,569,366	-5,883,121	-	-6,086,945	-6,600,747	-8,951,819	-	-5,304,185	-5,264,847	-5,756,936	-	5,412,604	-10,236,119
EBT Margin	-22.7%	-634	-517	-517	-474	-596	-762	-1,043	-1,966	-142	-112	-106	-112	-	-	-	-	-	-	-	-	-
Net Income	2.0%	-14,466,123	-14,754,029	-10,567,226	-8,208,951	-6,853,721	-7,604,839	-7,034,194	-7,790,987	-8,569,366	-4,632,935	-7,216,938	-6,086,945	-6,600,747	-3,782,424	-5,557,567	-5,304,185	-5,264,847	-696,158	-5,167,884	2,148,518	-10,236,119
Net Income Margin	-8.4%	-768	-708	-508	-454	-556	-776	-1,032	-1,958	-139	-100	-93.46	-92.08	-	-	-	-	-	-	-	-	-
Free Cashflow	-57.3%	-17,371,600	-11,041,625	-10,408,652	-6,283,594	-6,071,854	-5,471,978	-6,748,666	-6,498,121	-6,281,407	-3,097,132	-6,703,892	-6,010,571	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-17.1%	68.00	82.00	91.00	57.00	59.00	62.00	62.00	68.00	65.00	69.00	75.00	81.00	84.00	49.00	40.00	24.00	27.00	29.00	34.00	28.00	27.00
Current Assets	-20.2%	63.00	79.00	89.00	55.00	57.00	60.00	60.00	65.00	63.00	66.00	73.00	80.00	83.00	48.00	39.00	24.00	27.00	29.00	34.00	27.00	27.00
Cash Equivalents	-19.0%	35.00	44.00	53.00	20.00	25.00	43.00	43.00	49.00	46.00	54.00	67.00	73.00	76.00	42.00	35.00	17.00	12.00	17.00	20.00	15.00	18.00
Inventory	10.2%	2.00	2.00	-	-	-	-	269*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net PPE	2.1%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-16.0%	10.00	12.00	8.00	8.00	5.00	7.00	6.00	6.00	5.00	6.00	6.00	4.00	4.00	5.00	6.00	6.00	6.00	6.00	5.00	11.00	11.00
Current Liabilities	-16.4%	10.00	11.00	8.00	7.00	5.00	6.00	5.00	5.00	4.00	5.00	5.00	3.00	3.00	4.00	5.00	6.00	6.00	6.00	5.00	4.00	4.00
Shareholder's Equity	-17.3%	58.00	70.00	83.00	49.00	54.00	55.00	56.00	62.00	60.00	63.00	69.00	77.00	80.00	44.00	34.00	0.00	22.00	24.00	29.00	16.00	17.00
Retained Earnings	-4.5%	-336	-321	-306	-297	-285	-275	-267	-260	-252	-245	-237	-229	-224	-217	-211	-204	-200	-195	-190	-184	-184
Additional Paid-In Capital	0.6%	394	392	390	346	340	330	323	322	312	308	307	306	305	262	246	223	222	219	219	201	201
Shares Outstanding	0.0%	55.00	55.00	55.00	46.00	44.00	43.00	41.00	40.00	38.00	38.00	38.00	37.00	36.00	34.00	-	-	-	-	-	-	-
Float	-	-	-	-	180	-	-	-	164	-	-	-	208	-	-	-	208	-	-	-	209	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-61.1%	-17,310	-10,745	-8,697	-8,572	-10,393	-6,154	-5,995	-5,462	-6,744	-5,869	-5,503	-3,091	-6,690	-5,933	-7,312	-754	-7,966	-3,884	-3,964	164	-7,367
Share Based Compensation	100.8%	2,444	1,217	1,003	1,057	2,216	874	984	1,074	1,138	1,253	1,048	1,010	1,732	516	611	696	677	453	571	606	809
Cashflow From Investing	1396.3%	8,945	598	-586	-2,385	-14,686	-1.86	-114	594	-4,187	-7,129	-1,271	-208	-526	-1,847	3,243	5,045	985	296	-477	-3,874	-7,964
Cashflow From Financing	-120.8%	-97.12	468	42,899	5,350	7,200	6,046	437	8,411	3,004	-	-	177	41,581	15,322	21,943	-	2,835	-205	10,029	14.00	15,968

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CRMD Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Net sales		$ 65,408
Cost of sales		(3,734)
Gross profit		61,674
Operating Expenses:
Research and development	(13,155,125)	(10,679,549)
Selling, general and administrative	(35,802,663)	(20,006,093)
Total operating expenses	(48,957,788)	(30,685,642)
Loss From Operations	(48,957,788)	(30,623,968)
Other Income (Expense):
Interest income	2,681,851	326,016
Foreign exchange transaction (loss) income	(28,994)	37,145
Interest expense	(34,296)	(26,515)
Total other income	2,618,561	336,646
Net Loss Before Income Taxes	(46,339,227)	(30,287,322)
Tax benefit		585,617
Net Loss	(46,339,227)	(29,701,705)
Other Comprehensive Income (Loss):
Unrealized gain from investments	9,683	5,055
Foreign currency translation gain (loss)	1,682	(9,442)
Total other comprehensive gain (loss)	11,365	(4,387)
Comprehensive Loss	$ (46,327,862)	$ (29,706,092)
Net Loss Per Common Share – Basic (in Dollars per share)	$ (0.91)	$ (0.74)
Weighted Average Common Shares Outstanding – Basic (in Shares)	50,902,931	40,274,273

CRMD Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 43,642,684	$ 43,148,323
Restricted cash	77,453	124,102
Short-term investments	32,388,130	15,644,062
Inventories, net	2,106,345
Prepaid research and development expenses	353,574	11,016
Other prepaid expenses and current assets	882,214	623,672
Total current assets	79,450,400	59,551,175
Property and equipment, net	1,866,224	1,609,679
Restricted cash, long term	103,055	102,320
Operating lease right-of-use assets	640,278	775,085
TOTAL ASSETS	82,059,957	62,038,259
Current liabilities
Accounts payable	4,279,679	2,202,149
Accrued expenses	6,970,217	3,973,941
Operating lease liabilities, short-term	150,619	134,801
Total current liabilities	11,400,515	6,310,891
Operating lease liabilities, net of current portion	517,013	667,632
TOTAL LIABILITIES	11,917,528	6,978,523
COMMITMENTS AND CONTINGENCIES (Note 6)
STOCKHOLDERS’ EQUITY
Preferred stock - $0.001 par value: 2,000,000 shares authorized; 181,622 shares issued and outstanding at December 31, 2023 and 2022	182	182
Common stock - $0.001 par value: 160,000,000 shares authorized at December 31, 2023 and 2022; 54,938,258 and 42,815,196 shares issued and outstanding at December 31, 2023 and 2022, respectively	54,938	42,815
Accumulated other comprehensive gain	94,108	82,743
Additional paid-in capital	391,693,214	330,294,782
Accumulated deficit	(321,700,013)	(275,360,786)
TOTAL STOCKHOLDERS’ EQUITY	70,142,429	55,059,736
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 82,059,957	$ 62,038,259

About CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CEO	Mr. Joseph Todisco MBA
WEBSITE	cormedix.com
INDUSTRY	Biotechnology
EMPLOYEES	40

CorMedix Inc Frequently Asked Questions

What is the ticker symbol for CorMedix Inc? What does CRMD stand for in stocks?

CRMD is the stock ticker symbol of CorMedix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CorMedix Inc (CRMD)?

As of Thu May 09 2024, market cap of CorMedix Inc is 297.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRMD stock?

You can check CRMD's fair value in chart for subscribers.

What is the fair value of CRMD stock?

You can check CRMD's fair value in chart for subscribers. The fair value of CorMedix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CorMedix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CorMedix Inc a good stock to buy?

The fair value guage provides a quick view whether CRMD is over valued or under valued. Whether CorMedix Inc is cheap or expensive depends on the assumptions which impact CorMedix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRMD.

What is CorMedix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, CRMD's PE ratio (Price to Earnings) is -5.92 and Price to Sales (PS) ratio is 4.55 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CorMedix Inc's stock?

In the past 10 years, CorMedix Inc has provided -0.041 (multiply by 100 for percentage) rate of return.